Merck Sharp + Dohme Corp.

Hanmi Xi

W Mark Eickhoff

Wei Xu

Craig B Ikeda

Leonardo Resende Allain

Mary Ann Johnson

Chad D Brown

Francis J Flanagan, Jr

Paresh B Patel

Rebecca Nofsinger

Melanie Marota

Lisa Lupton

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

Treatment of migraine

Pharmaceutical formulations for the treatment of migraine

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein 'R' is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

Tablet formulation for CGRP active compounds

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein 'R' is independently H or &#x2014;F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released. 

Growing community of inventors

Furlong, PA, United States of America

Hanmi Xi